Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Dr Yvette Drew.

Newcastle AuthorsTitleYearFull text
Dr Yvette Drew
Professor Ruth Plummer
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study2024
Dr Ann Fisher
Dr Yvette Drew
Dr Rachel O'Donnell
Enteric Type Bartholin Gland Adenocarcinoma: An Unusual Variant of a Rare Neoplasm2021
Dr Sweta Sharma Saha
Lucy Gentles
Dominik Brecht
Dr Rachel O'Donnell
Professor Nicola Curtin
et al.
Genomic, transcriptomic, and functional alterations in DNA damage response pathways as putative biomarkers of chemotherapy response in ovarian cancer2021
Lucy Gentles
Professor Nicola Curtin
Dr Yvette Drew
Dr Rachel O'Donnell
Integration of computer-aided automated analysis algorithms in the development and validation of immunohistochemistry biomarkers in ovarian cancer2021
Alice Bradbury
Dr Rachel O'Donnell
Dr Yvette Drew
Professor Nicola Curtin
Dr Sweta Sharma Saha
et al.
Characterisation of ovarian cancer cell line NIH-OVCAR3 and implications of genomic, transcriptomic, proteomic and functional DNA damage response biomarkers for therapeutic targeting2020
Dr Nicola Cresti
Dr Yvette Drew
First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor2020
Dr Yvette Drew
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non- BRCA1/2-Mutant Cancers2020
Alice Bradbury
Sally Hall
Professor Nicola Curtin
Dr Yvette Drew
Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?2020
Dr Yvette Drew
Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer2020
Dr Asima Mukhopadhyay
Dr Yvette Drew
Liz Matheson
Dr Mo Salehan
Lucy Gentles
et al.
Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors2019
Lucy Gentles
Bojidar Goranov
Elizabeth Matheson
Dr Ashleigh Herriott
Dr Angelika Kaufmann
et al.
Exploring the frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types2019
Professor Nicola Curtin
Dr Yvette Drew
Dr Sweta Sharma Saha
Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy2019
Dr Yvette Drew
An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in gremlin BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC)2018
Lucy Gentles
Liz Matheson
Dr Nicholas Bown
Alice Bradbury
Maryam Zanjirband Zanjirband
et al.
Characterization and drug sensitivity of a novel human overian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor2018
Dr Sarah Fordham
Dr Helen Blair
Dr Claire Elstob
Professor Ruth Plummer
Dr Yvette Drew
et al.
Inhibition of ATR acutely sensitises acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase2018
Dr Yvette Drew
A phase I-II study of the oral PARP inhibitor Rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumours2017
Dr Miranda Patterson
Dr Yvette Drew
Professor Nicola Curtin
PARP2017
Dr Stuart Rundle
Alice Bradbury
Dr Yvette Drew
Professor Nicola Curtin
Targeting the ATR-CHK1 Axis in Cancer Therapy2017
Dr David Jamieson
Melanie Griffin
Julieann Sludden
Dr Yvette Drew
Dr Nicola Cresti
et al.
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours2016
Dr Yvette Drew
Homologous recombination deficiency and ovarian cancer2016
Dr Ganiy Abdulrahman
Elizabeth Matheson
Dr Yvette Drew
Professor Nicola Curtin
Dr Asima Mukhopadhyay
et al.
Investigating PARP inhibitor sensitisation by hyperthermia and HSP90 inhibition2016
Dr Yvette Drew
Dr Martin Highley
Julieann Sludden
Dr James Murray
Dr David Jamieson
et al.
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly (ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer2016
Elizabeth Matheson
Dr Mo Salehan
Dr Asima Mukhopadhyay
Professor Nicola Curtin
Dr Yvette Drew
et al.
Preclinical studies of the PARP inhibitor olaparib in combination with imatinib in BRCA stratified ovarian cancer2016
Dr Yvette Drew
Professor Alastair Greystoke
Professor Ruth Plummer
A first-in-human dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of oral 2-hydroxyoleic acid (2-OHOA) in adult patients (pt) with advanced solid tumors including grade III/IV glioblastoma multiforme (GBM).2015
Dr Yvette Drew
A Phase 2 open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation2015
Dr Yvette Drew
A phase II open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation2015
Dr Yvette Drew
The development of PARP inhibitors in ovarian cancer: from bench to bedside2015
Professor Ruth Plummer
Dr Nicola Cresti
Dr Yvette Drew
Dr Peter Stephens
Dr Jared Thornton
et al.
Phase 1 study of the PARP inhibitor E7449 as a single agent in patients with advanced solid tumors or B-cell lymphoma2014
Dr Yvette Drew
Ajay Gupta
Professor Ruth Plummer
A Phase 1 Study of Oral or Intravenous Rucaparib in Combination in Combination with Platinum-Containing Chemotherapeutic Regimens: Analysis of Patients with Ovarian or Peritoneal Tumors2013
Dr Nicola Cresti
Dr Yvette Drew
Professor Ruth Plummer
A phase I study of oral rucaparib in combination with carboplatin2013
Bojidar Goranov
Dr Yvette Drew
Jonathon Graham
Dr Rachel Pearson
Academic opportunities within clinical oncology training2013
Dr Jane Margetts
Dr Yvette Drew
Dr Peter Stephens
Professor Alan Calvert
Professor Ruth Plummer
et al.
Erratum to: Phase I study of PM00104 (Zalypsis (R)) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors (vol 31, pg 623, 2013 Doi: 10.1007/s10637-012-9843-5)2013
Dr Jane Margetts
Dr Yvette Drew
Professor Ruth Plummer
Phase I study of PM00104 (Zalypsis (R)) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors2013
Dr Yvette Drew
Dr Evan Mulligan
Wan Vong
Huw Thomas
Suzanne Kyle
et al.
Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA22011
Rachel Daniel
Dr Agata Rozanska
Dr Evan Mulligan
Dr Yvette Drew
Huw Thomas
et al.
Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-0146992010
Dr Asima Mukhopadhyay
Dr Ahmed Elattar
Dr Aiste McCormick
Sarah Wilkinson
Dr Yvette Drew
et al.
Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors2010
Dr Yvette Drew
Professor Ruth Plummer
The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer2010
Dr Evan Mulligan
Tomasz Zaremba
Dr Yvette Drew
Professor Ruth Plummer
Professor Nicola Curtin
et al.
[abstract] Validated sensitive immunological determination of PARP-1 protein levels and activity in cultured cells and human lymphocytes2009
Dr Agata Rozanska
Huw Thomas
Dr Evan Mulligan
Dr Yvette Drew
Deborah Castelbuono
et al.
Inhibition of Poly (ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma2009
Dr Yvette Drew
Professor Ruth Plummer
PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications2009
Dr Yvette Drew
Suzanne Kyle
Professor Richard Edmondson
Professor Ruth Plummer
Professor Nicola Curtin
et al.
Investigating DNA double strand break formation and repair in response to the PARP inhibitor AG014699 in cell lines defective in Homologous Recombination: a role for PARP inhibitors in sporadic cancers? [abstract]2008
Professor Alan Calvert
Professor Ruth Plummer
Professor Nicola Curtin
Professor Richard Edmondson
Dr Yvette Drew
et al.
PARP inhibitors in cancer treatment2008
Dr Yvette Drew
Professor Alan Calvert
The Potential of PARP Inhibitors in Genetic Breast and Ovarian Cancers2008
Dr Yvette Drew
Professor Alan Calvert
The potential of PARP inhibitors in genetic breast and ovarian cancers2008